LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine

A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation. (NCI Thesaurus)

YOU MAY ALSO LIKE

LY6E wt Allele

Human LY6E wild-type allele is located in the vicinity of 8q24.3 and is approximately 4 kb in length. This allele, which encodes…

LY6E Gene

This gene plays a role in signal transduction.

LY353381 hydrochloride

A substance being studied in the treatment of osteoporosis and breast cancer. LY353381 hydrochloride is made in the laboratory and binds to…

LY335979

A substance being studied in the treatment of cancer. LY335979 may help kill cancer cells that are resistant to anticancer drugs. Also…

LY317615

A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. LY317615…

LY293111

A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called leukotriene B4 receptor…